# ResMed (RMD) Q1 FY2027 earnings

Results filed 2026-10-29 for the quarter ended 2026-09-30. Source page: https://earnings.opennash.com/companies/rmd/2027-q1/
Press release and documents: https://www.sec.gov/Archives/edgar/data/943819/000119312526437783/0001193125-26-437783-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

ResMed closed the MatrixCare divestiture and launched the AirTouch F40 fabric mask, refocusing on core sleep and breathing health and its connected digital ecosystem.

ResMed's quarter was driven by demand for sleep devices and masks in both the Americas and the rest of the world. It launched the AirTouch F40, its third fabric mask, plus the AirCurve 11 ST/ST-A bilevel device in the U.S. It also closed the MatrixCare sale and added partnerships with Eight Sleep and ŌURA to bring more people into sleep care.
Management is steering toward its core sleep and breathing business, a connected ecosystem and its 2030 strategy, backed by about $1.5 billion of planned buybacks and tuck-in M&A of up to about $500 million. The main tension is a second-half squeeze on rest-of-world device sales as the France fleet renewal concludes, plus a roughly 130 bps revenue headwind from Astral.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenue | $1,415 | up 6% from a year ago | GAAP |
| Net income | $418 | up 20% from a year ago | GAAP |
| Diluted EPS | $2.92 | up 23% from a year ago | GAAP |
| Non-GAAP diluted EPS | $2.91 | up 14% from a year ago | non-GAAP |
| Gross margin | 61.5% | up 30 bps from a year ago | GAAP |
| Non-GAAP gross margin | 62.5% | up 50 bps from a year ago | non-GAAP |
| Operating margin | 32.0% | down 140 bps from a year ago | GAAP |
| Non-GAAP operating margin | 35.8% | down 30 bps from a year ago | non-GAAP |
| Operating cash flow | $422 million | down 8% from a year ago |  |
| Free cash flow | $374 million | down 10% from a year ago |  |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Americas Sleep Devices | $436 | up 8% (6% core constant currency) |
| Americas Masks and other | $397 | up 10% |
| Rest of World Sleep Devices | $280 | up 12% (13% core constant currency) |
| Rest of World Masks and other | $143 | up 12% (11% core constant currency) |
| Total Sleep and Breathing Health | $1,260 | up 8% (7% core constant currency) |
| Residential Care Software | $155 | down 7% (up 5% core constant currency) |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Core constant currency revenue growth | fiscal year 2027 | 5 - 7% growth |
| Reported revenue | fiscal year 2027 | $5.75 - $5.85 Billion |
| Non-GAAP diluted EPS | fiscal year 2027 | $12.00 - $12.25 |

## Key takeaways

1. **AirTouch F40 extends ResMed's fabric mask line** ResMed launched the AirTouch F40 in the U.S. as its third fabric mask. Its ComfiSoft cushion adapts through the night, and 91% rated it comfortable at initial fitting.
2. **Personalized myAir features aim to lift compliance** Resmed's AI-powered myAir, with the Dawn GenAI coach, reached 2.1M+ inquiries, up 40%. It reports a 4.3% increase in 30-day compliance versus default settings.
3. **MatrixCare exit sharpens focus on core sleep** The MatrixCare sale closed September 1, 2026. Management says it improves the growth, mix and focus of Residential Care Software, whose remaining Brightree and MEDIFOX DAN businesses grew 8%.
4. **GLP-1 data counters fears of lower CPAP demand** An IQVIA analysis of 3,307,000 patients found GLP-1 users were 1170 bps more likely to initiate PAP therapy. Resupply rates were also higher, by 350 bps at 1 year and 730 bps at 3 years.
5. **Partnerships and Nidra widen the patient funnel** Eight Sleep and ŌURA partnerships connect sleep insights to ResMed's assessment and care pathways. ResMed also closed the Nidra restless legs syndrome acquisition on June 1, 2026, and is prioritizing commercial coverage.

## Questions

**What new products did ResMed launch this quarter?** ResMed launched the AirTouch F40, its third fabric CPAP mask, in the U.S. It also introduced the AirCurve 11 ST/ST-A bilevel device and expanded myAir personalization features.
**How is ResMed responding to GLP-1 weight-loss drugs?** It points to an IQVIA analysis of 3,307,000 patients showing GLP-1 users were 1170 bps more likely to initiate PAP therapy and had higher resupply rates.
**Why did ResMed sell MatrixCare?** Management says the sale accelerates growth and profitability of core Residential Care Software, improves mix and sharpens execution focus. It closed on September 1, 2026.
**What is ResMed doing to reach more undiagnosed sleep apnea patients?** It is partnering with Eight Sleep and ŌURA and running marketing campaigns, including one with NASCAR driver Tyler Reddick. In the ŌURA pathway, about 72% of assessment takers were undiagnosed.
**What risks does ResMed flag for the rest of fiscal 2027?** It flags second-half pressure on rest-of-world sleep devices as the France fleet renewal concludes, a roughly 130 bps revenue headwind from Astral, and a larger FX headwind of about 60 bps.

## Slides and investor documents

- [Presentation    PDF](https://investor.resmed.com/_assets/_5bcd8acc7e1b5c73a62283d752dd0b96/resmed/db/2598/48783/presentation/RMD_1Q27_Earnings_Presentation_29OCT26.pdf) (Slide deck)
- [Q1 FY27 Earnings Presentation   View Quarterly Presentation](https://investor.resmed.com/_assets/_5bcd8acc7e1b5c73a62283d752dd0b96/resmed/db/2579/48784/pdf/RMD_1Q27_Earnings_Presentation_29OCT26.pdf) (Slide deck)
- [Transcript](https://investor.resmed.com/_assets/_5bcd8acc7e1b5c73a62283d752dd0b96/resmed/db/2598/48783/webcast_transcript/RMD_1Q27_Earnings_Transcript_29OCT26.pdf) (Company's official transcript)

